Awad Elias K, Moore Marc, Liu Hui, Ciszewski Lukasz, Lambert Laura, Korf Bruce R, Popplewell Linda, Kesterson Robert A, Wallis Deeann
Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Centre of Biomedical Sciences, Department of Biological Sciences, Royal Holloway, University of London, Egham, Surrey TW20 0EX, UK.
J Pers Med. 2021 Dec 7;11(12):1320. doi: 10.3390/jpm11121320.
Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder with almost 3000 different disease-causing variants within the gene identified. Up to 44% of these variants cause splicing errors to occur within pre-mRNA. A recurrent variant in exon 13, c.1466A>G; p.Y489C (Y489C) results in the creation of an intragenic cryptic splice site, aberrant splicing, a 62 base pair deletion from the mRNA, and subsequent frameshift. We investigated the ability of phosphorodiamidate morpholino oligomers (PMOs) to mask this variant on the RNA level, thus restoring normal splicing. To model this variant, we have developed a human iPS cell line homozygous for the variant using CRISPR/Cas9. PMOs were designed to be 25 base pairs long, and to cover the mutation site so it could not be read by splicing machinery. Results from our in vitro testing showed restoration of normal splicing in the RNA and restoration of full length neurofibromin protein. In addition, we observe the restoration of neurofibromin functionality through GTP-Ras and pERK/ERK testing. The results from this study demonstrate the ability of a PMO to correct splicing errors in variants at the RNA level, which could open the door for splicing corrections for other variants in this and a variety of diseases.
1型神经纤维瘤病(NF1)是一种常染色体显性遗传病,在该基因中已鉴定出近3000种不同的致病变体。其中高达44%的变体导致前体mRNA内出现剪接错误。外显子13中的一个反复出现的变体,c.1466A>G;p.Y489C(Y489C)导致产生一个基因内隐蔽剪接位点、异常剪接、mRNA缺失62个碱基对以及随后的移码。我们研究了磷酰胺吗啉代寡聚物(PMO)在RNA水平上掩盖该变体的能力,从而恢复正常剪接。为了模拟这个变体,我们使用CRISPR/Cas9开发了一个对该变体纯合的人诱导多能干细胞系。PMO被设计成长度为25个碱基对,并覆盖突变位点,使剪接机制无法读取该位点。我们的体外测试结果显示,RNA恢复了正常剪接,全长神经纤维瘤蛋白也得以恢复。此外,我们通过GTP-Ras和pERK/ERK测试观察到神经纤维瘤蛋白功能的恢复。这项研究的结果证明了PMO在RNA水平上纠正变体剪接错误的能力,这可能为纠正该疾病及多种疾病中的其他变体剪接打开大门。